J Am Heart Assoc: 预测缺血性卒中后的再入院模型

2015-09-26 phylis 译 MedSci原创

背景:减少患者再入院是卒中护理的主要改革部分。当前的再入院预测模型准确性较差,并且仅局限于急性入院的数据。研究人员假设基于全国范围内的急性期后护理数据库的患者因素可能改善预测模型。方法:应用2008年的国际疾病分类(第九版)确诊并筛选出大于65岁缺血性卒中患者。应最小数据集(MDS)对患者急性期后护理进行综合评估。应用logistic回归建立风险校正再入院模型。协变量为MDS变量。结果:在3917

背景:减少患者再入院是卒中护理的主要改革部分。当前的再入院预测模型准确性较差,并且仅局限于急性入院的数据。研究人员假设基于全国范围内的急性期后护理数据库的患者因素可能改善预测模型。

方法:应用2008年的国际疾病分类(第九版)确诊并筛选出大于65岁缺血性卒中患者。应最小数据集(MDS)对患者急性期后护理进行综合评估。应用logistic回归建立风险校正再入院模型。协变量为MDS变量。

结果:在39178名患者中因急性卒中入院后直接进入疗养院,有29338(75%)名患者完成了MDS的评估。30天后,再入院和死亡人数分别为8448(21%)和2791(7%)。危险校正模型确定多个独立因各种原因再入院的预测因子。应用MDS数据建立的再入院模型的c-statistic值为0.65(95%CI: 0.64  0.66)。高水平的社会交往、疗养院的质量都与再入院率下降相关。(OR=0.71  95%CI: 0.55  0.92)。

结论:与先前模型仅用老年保健医疗A部分的数据相比,来自急性后护理数据集的临床资料c-stastistic仅轻度升高。个体水平的特征不能充分的解释急性再入院的风险。

原文出处:

Fehnel CR, Lee Y, Wendell LC,et al.Post-Acute Care Data for Predicting Readmission After Ischemic Stroke: A Nationwide Cohort Analysis Using the Minimum Data Set. J Am Heart Assoc. 2015 Sep 22


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671198, encodeId=539c16e11985f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Sep 07 18:48:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806029, encodeId=1b70180602922, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 21 11:48:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892678, encodeId=78f118926e8e5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Jul 05 02:48:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356010, encodeId=922513560106d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562320, encodeId=9f461562320c7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671198, encodeId=539c16e11985f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Sep 07 18:48:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806029, encodeId=1b70180602922, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 21 11:48:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892678, encodeId=78f118926e8e5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Jul 05 02:48:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356010, encodeId=922513560106d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562320, encodeId=9f461562320c7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671198, encodeId=539c16e11985f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Sep 07 18:48:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806029, encodeId=1b70180602922, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 21 11:48:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892678, encodeId=78f118926e8e5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Jul 05 02:48:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356010, encodeId=922513560106d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562320, encodeId=9f461562320c7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671198, encodeId=539c16e11985f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Sep 07 18:48:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806029, encodeId=1b70180602922, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 21 11:48:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892678, encodeId=78f118926e8e5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Jul 05 02:48:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356010, encodeId=922513560106d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562320, encodeId=9f461562320c7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
    2015-09-28 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671198, encodeId=539c16e11985f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Sep 07 18:48:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806029, encodeId=1b70180602922, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 21 11:48:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892678, encodeId=78f118926e8e5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Jul 05 02:48:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356010, encodeId=922513560106d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562320, encodeId=9f461562320c7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 28 09:48:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
    2015-09-28 slcumt

相关资讯

Geriatr Gerontol Int:卒中前痴呆对其缺血性卒中的影响

目的:这篇研究的主要目的是确定卒中前痴呆(PSD)是否影响老年缺血性卒中患者的短期功能预后。方法:对老年缺血性卒中患者进行回顾性病例对照研究。应用功能独立测量量表(FIM)对患者入院和出院时进行功能预后评估。应用t检验,卡方检验,多次线性回归以及logistics回归分析数据。结果:急性缺血性卒中患者919名,其中11.5%诊断为PSD。与非PSD患者相比,PSD患者,存活时间较短,女性患者比例较

Atherosclerosis:空腹及餐后甘油三酯和颈动脉内膜厚度的关系

背景:颈总动脉内膜厚度(CCA-IMT)是动脉粥样硬化的一种检测指标。甘油三酯在CCA-IMT中的作用尚有争议。研究人员旨在确定是否空腹及餐后甘油三酯与CCA-IMT相关。 方法:招募2009年1月到2014年1月期间参与柏林“Cream和Sugar”研究中的急性缺血性卒中患者,并对其进行颈动脉超声检测的患者。第一次缺血性卒中后,对患者进行3-7天口服糖和甘油三酯耐受实验。根据甘油三酯的代谢情况,

Int J Stroke:急性缺血性卒中药物治疗还是血管内血栓切除?

大血管梗塞的急性缺血性卒中患者行静脉溶栓治疗,血管再通效果较差。最近的研究表明血管内治疗,患者血管再通及预后较单纯药物治疗好。系统性综述和meta-分析调查血管内血栓切除术的相关随机对照试验优势,并且至少有25%的患者应用血栓切除设备进行急性缺血性卒中患者治疗,并且这些患者未进行药物治疗。对血管内血栓切除和药物治疗急性缺血性卒中患者的疗效进行系统性综述和meta-分析。我们研究选取了437个研究,

Eur J Neurol:患者自述心血管家族史可信吗?

家族史是遗传危险因素的指标。应用家族史这个指标可以反映家族中真正的疾病。这篇研究为了分析中青年缺血性卒中患者自称的心血管疾病(CVD)的家族史和患者父母报告的一致性。应用标准化问卷调查了15-60岁的缺血性卒中的患者和他们父母。登记存在CVD和CVD家族史的患者。应用KAPPA统计分析患者自述和父母报告一致的敏感性,特异性,预测价值以及似然比。应用回归分析非一致性患者的特征。父亲和母亲的的反应率没

BMJ Open:抗癫痫药与缺血性卒中和心肌梗死发生的关系

目的:肝酶诱导的抗癫痫药物(AEDs)通过诱导细胞色素P450增加血浆中的脂质及其他动脉粥样硬化标志物,因此可能会增加血管事件的发生。研究人员根据AED代谢的酶特性旨在评估其对缺血性卒中和心肌梗死(MI)发生的风险。设计:病例对照分析的群体队列研究。英国临床实践研究数据链中的650个普通医生的医业。受试者:招募1990年1月到2013年4月间252407名应用AED的患者,患者年龄在18岁以上。每

Clin Chim Acta:血管反应素-1对急性缺血性卒中患者预后的预测价值

血管反应素-1是血管再生的有效调节剂。脑出血的大鼠模型中脑中血管反应素-1的表达增加。当前的研究主要是确定血浆中血管反应素-1浓度的变化以及评估血浆血管反应素-1浓度对缺血性卒中患者长期的死亡率和功能预后的预测价值。这篇研究包括192名患者,150名健康者作为对照。应用酶联免疫吸附试验测定血浆中血管反应素-1的浓度。不利预后以mRS分数大于3为标准。应用多变量分析血浆血管反应素-1浓度和6个月临床